MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
Methyllycaconitine citrate
CAS No. : 351344-10-0
MCE 国际站:Methyllycaconitine citrate
产品活性:Methyllycaconitine citrate 是 α7 神经元烟碱型乙酰胆碱受体 (α7nAChR) 的特异性拮抗剂,具有血脑屏障通透性。
研究领域:Membrane Transporter/Ion Channel | Neuronal Signaling
作用靶点:nAChR
In Vitro: Pretreatment with 5 and 10 μM Methyllycaconitine citrate (MLA) inhibits the decreased cell viability induced by Aβ25-35. Cell viability does not decrease after exposure to Methyllycaconitine citrate (2.5, 5, 10, 20 μM). Aβ25-35 treatment increases LC3-II levels, which is inhibited by administration of Methyllycaconitine citrate. Methyllycaconitine citrate also inhibits Aβ-induced autophagosome accumulation in SH-SY5Y cells. Flow cytometry also demonstrates decreased MDC-labeled vacuoles with Methyllycaconitine citrate treatment.
In Vivo: Methyllycaconitine citrate (MLA) (6 mg/kg) given alone intraperitoneally does not cause climbing behavior when compare with the saline group. Pretreatment with Methyllycaconitine citrate significantly inhibits methamphetamine (METH)-induced climbing behavior, by about 50%. Methyllycaconitine citrate does not modify either basal locomotor activity or METH-induced hyperlocomotion. The METH-induced depletion of dopamine neuron terminals is attenuated in mice pretreated with Methyllycaconitine citrate (250±43 fmol/mg, n=7). A direct effect of Methyllycaconitine citrate on body temperature is ruled out because Methyllycaconitine citrate does not affect basal body temperature (37.0±0.5°C, n=5) or reduce the METH-induced hyperthermia (38.2±0.4°C, n=6, MLA+METH group, n.s. versus METH group).
相关产品:Bioactive Compound Library Plus | Membrane Transporter/Ion Channel Compound Library | Neuronal Signaling Compound Library | CNS-Penetrant Compound Library | Neurotransmitter Receptor Compound Library | Anti-Parkinson's Disease Compound Library | Neurodegenerative Disease-related Compound Library | Antidepressant Compound Library | Heterocyclic Compound Library | Membrane Protein-targeted Compound Library | Membrane Receptor-targeted Compound Library | Highly Selective Inhibitors Library | Ion Channel Compound Library | Acetylcholine chloride | PNU-282987 | Carbamoylcholine chloride | GTS-21 dihydrochloride | Mecamylamine hydrochloride | Choline chloride | Benzethonium chloride | COG 133 TFA | D-Tubocurarine chloride pentahydrate | Arecoline hydrobromide | α-Bungarotoxin | PNU-120596 | Spinosad | Varenicline | Rocuronium Bromide | Levamisole | Monepantel | Anabasine | Hydroxybupropion | Lobeline hydrochloride | Cisatracurium besylate | Dequalinium Chloride | PHA-543613 | Hexamethonium Bromide | Vecuronium bromide | Adiphenine hydrochloride | Dihydro-β-erythroidine hydrobromide
热门产品线:重组蛋白 | 药物筛选 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
品牌介绍:
• MCE (MedChemExpress) 拥有200 多种全球独家化合物库,我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物;
• 50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域;
• 产品种类涵盖各种重组蛋白,多肽,常用试剂盒 ,更有 PROTAC、ADC 等特色产品,广泛应用于新药研发、生命科学等科研项目;
• 提供虚拟筛选,离子通道筛选,代谢组学分析检测分析,药物筛选等专业技术服务;
• 设有专业的实验中心和严格的质控、验证体系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告,确保产品的高纯度、高品质;
• 产品的生物活性多经各国客户实验验证;
• Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果;
• 专业团队跟踪最新的制药及生命科学研究进展,为您提供全球最新的活性化合物;
• 与世界各大制药公司及知名科研机构建立了长期的合作。